H. Léna

Inserm — France

Medicine · Health Sciences

30h-index7.5kcitations211works11.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(81), Lung Cancer Research Studies(58), Lung Cancer Diagnosis and Treatment(45), Cancer Immunotherapy and Biomarkers(21), Neuroendocrine Tumor Research Advances(18)

Publications208 total

RWD56 Descriptive Comparison of Patient Characteristics and Treatment Patterns in Metastatic NSCLC: US and France Cohorts to Inform Transportability
Value in Health·2025
Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study
Oncology and Therapy·2025Open Access
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis
ESMO Open·2025· 5 citedOpen Access
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Nature Medicine·2025· 19 citedOpen Access
In vivo and in vitro evolution of small cell lung cancer molecular subtypes under cytotoxic treatment
Revue des Maladies Respiratoires·2025
Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary
Future Oncology·2025· 1 citedOpen Access
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
Frontiers in Oncology·2025· 1 citedOpen Access
FALCONS, une étude rétrospective non interventionnelle chez des patients atteints de CBNPC réséqué utilisant la base de données EPITHOR : premières analyses
Revue des Maladies Respiratoires Actualités·2025
Évaluation de la prise en charge des carcinomes bronchopulmonaires sarcomatoïdes métastatiques : analyse de la base nationale ESME
Revue des Maladies Respiratoires Actualités·2025
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
The Lancet Respiratory Medicine·2024· 13 cited
Place de l’immunothérapie dans les CBNPC de stade III non résécables
Revue des Maladies Respiratoires Actualités·2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Journal of Clinical Oncology·2024· 130 citedOpen Access
1218P FALCONS, a non-interventional retrospective study in resected NSCLC patients using the EPITHOR database, first analysis
Annals of Oncology·2024Open Access
Caractéristiques cliniques et séquences thérapeutiques des patients atteints de cancer bronchique non à petites cellules (CBNPC) métastatique avec mutation KRAS G12C traités par sotorasib dans l’ATUc
Revue des Maladies Respiratoires Actualités·2024
Profil des patients porteurs d’un cancer bronchique non à petites cellules avancé présentant un contrôle prolongé sous immunothérapie : résultats de la cohorte BREATH
Revue des Maladies Respiratoires Actualités·2024
Test de concordance de script et évaluation du raisonnement clinique pour les cancers bronchiques localement avancés
Revue des Maladies Respiratoires Actualités·2023
1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Annals of Oncology·2023· 1 citedOpen Access
Perspectives thérapeutiques dans la prise en charge des CBNPC de stade III non résécables
Revue des Maladies Respiratoires Actualités·2023
Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
2023Open Access
Data from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
2023Open Access
page 1 of 11Next →

Frequent Co-authors

G. Robinet(14), A. Vergnenègre(13), C. Chouaïd(12), Julien Mazières(11), Fabrice Barlési(11), Denis Moro‐Sibilot(9), P. Fournel(8), M. Pérol(8), Gérard Zalcman(7), B. Desrues(7), Éric Dansin(6), I. Monnet(6), P. Thomas(5), C. Belleguic(5), Virginie Westeel(5), H. Le Caer(5), Nicolas Girard(5), R. Gervais(5), Franck Morin(5), Clarisse Audigier-Valette(5)